🔗 Share this article Patients Stopping Slimming Medications Gain Back Pounds Four Times Faster Compared to People Using Diet and Exercise Obesity treatment involves ongoing approaches. New research indicates that people who stop using popular GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who stop conventional diet and exercise programs. Published data in a leading medical journal demonstrates that while overweight individuals can lose a large proportion of their total mass while on the medication, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation. "People buying such medications should be informed of the potential of fast rebound weight gain when the medication concludes," cautioned researcher Dr. Susan Jebb. This pace of regain suggests a return to pre-treatment weight within about one and a half years. Analyzing Treatments The analysis, which looked at 37 of studies involving thousands of participants, contrasted the effects of the injectable medications with conventional dieting. Researchers emphasize that people who lose weight through diet and exercise typically have a more gradual weight regain—perhaps 100 grams monthly—once they finish. Explaining the Rapid Rebound Nutrition scientists believe the way of the jabs accounts for the accelerated regain. The injections copy a natural hormone called glucagon-like peptide-1, which helps regulate appetite. "Long-term administration of GLP-1 concentrations several times higher than normal might result in the body to produce less of its endogenous GLP-1, and could reduce sensitivity to its actions," noted Dr. Adam Collins, a dietetics researcher. "Discontinuation of this hormone supplement means appetite is unsuppressed, making excessive eating a significant risk." A Chronic Condition? Medical guidelines suggest the injections for people with obesity-related health risks, accompanied by recommended lifestyle changes. Professionals say that, due to the significant potential of relapse, the treatment is often life-long. This perspective is echoed by drug manufacturers, who state that the findings "underscore the persistent character of obesity," akin to managing diseases like hypertension. User Testimonies People who have stopped the jabs report a powerful return of appetite. "It felt as if something flipping and you become extremely hungry," described an individual. The struggle is exacerbated if users have not developed permanent dietary or behavioural changes during therapy. Widespread Interest Survey data indicate that a significant number of adults in the UK have used these injections in the past year, with interest being substantial. Use is greater among women than males. The 40s and 50s age group shows the greatest usage rates. Many obtain the medications through private healthcare rather than public health services. In conclusion, researchers emphasize that while the jabs are potent tools for shedding pounds, they are not a permanent fix and lasting health benefits likely depends on integrated behavioural management.
Obesity treatment involves ongoing approaches. New research indicates that people who stop using popular GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who stop conventional diet and exercise programs. Published data in a leading medical journal demonstrates that while overweight individuals can lose a large proportion of their total mass while on the medication, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation. "People buying such medications should be informed of the potential of fast rebound weight gain when the medication concludes," cautioned researcher Dr. Susan Jebb. This pace of regain suggests a return to pre-treatment weight within about one and a half years. Analyzing Treatments The analysis, which looked at 37 of studies involving thousands of participants, contrasted the effects of the injectable medications with conventional dieting. Researchers emphasize that people who lose weight through diet and exercise typically have a more gradual weight regain—perhaps 100 grams monthly—once they finish. Explaining the Rapid Rebound Nutrition scientists believe the way of the jabs accounts for the accelerated regain. The injections copy a natural hormone called glucagon-like peptide-1, which helps regulate appetite. "Long-term administration of GLP-1 concentrations several times higher than normal might result in the body to produce less of its endogenous GLP-1, and could reduce sensitivity to its actions," noted Dr. Adam Collins, a dietetics researcher. "Discontinuation of this hormone supplement means appetite is unsuppressed, making excessive eating a significant risk." A Chronic Condition? Medical guidelines suggest the injections for people with obesity-related health risks, accompanied by recommended lifestyle changes. Professionals say that, due to the significant potential of relapse, the treatment is often life-long. This perspective is echoed by drug manufacturers, who state that the findings "underscore the persistent character of obesity," akin to managing diseases like hypertension. User Testimonies People who have stopped the jabs report a powerful return of appetite. "It felt as if something flipping and you become extremely hungry," described an individual. The struggle is exacerbated if users have not developed permanent dietary or behavioural changes during therapy. Widespread Interest Survey data indicate that a significant number of adults in the UK have used these injections in the past year, with interest being substantial. Use is greater among women than males. The 40s and 50s age group shows the greatest usage rates. Many obtain the medications through private healthcare rather than public health services. In conclusion, researchers emphasize that while the jabs are potent tools for shedding pounds, they are not a permanent fix and lasting health benefits likely depends on integrated behavioural management.